Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

@article{Rubino2015PopulationPA,
  title={Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.},
  author={Chris M Rubino and Sujata M. Bhavnani and Greg Moeck and S Eralp Bellibas and Paul G. Ambrose},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 6},
  pages={3365-72}
}
Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. Here we describe oritavancin population pharmacokinetics and the impact of patient-specific covariates on drug exposure variability. Concentration-time data were analyzed from two phase 3 clinical trials, SOLO I and SOLO II, in which oritavancin was administered as a single 1,200-mg dose to patients with acute bacterial skin and skin structure infections. A total of 1,337 drug concentrations from 297… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Oritavancin pharmacokinetic - pharmacodynamic analyses for efficacy based on data from patients with acute bacterial skin and skin structure infections enrolled in SOLO I and II , abstr A - 1309

  • OO Okusanya, D Lehoux, +4 authors SM Bhavnani
  • 2014

Pharmacokinetic - pharmacodynamic evaluation of oritavancin against Staphylococcus aureus using data from a murine - thigh infection model , abstr A - 620

  • OO Okusanya, D Lehoux, +7 authors TR Parr
  • 2012

ADAPT 5 User's Guide: 482 Pharmacokinetic/Pharmacodynamic Systems Analysis Software

  • DZ D'Argenio, A Schumitzky, X. Wang
  • Biomedical Simulations Resource;
  • 2009
1 Excerpt

ADAPT 5 user ’ s guide : pharmacokinetic / pharmacodynamic systems analysis software

  • H Akaike
  • 2009

Similar Papers

Loading similar papers…